Marc M Oshiro

Summary

Affiliation: University of Arizona
Country: USA

Publications

  1. ncbi Epigenetic silencing of DSC3 is a common event in human breast cancer
    Marc M Oshiro
    Department of Pharmacology, Arizona Cancer Center, University of Arizona, Tucson, AZ, USA
    Breast Cancer Res 7:R669-80. 2005
  2. ncbi Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression
    Marc M Oshiro
    Bone Marrow Transplant Program, Arizona Cancer Center and Department of Pharmacology and Toxicology, The University of Arizona, Tucson, AZ 85724, USA
    Oncogene 22:3624-34. 2003
  3. ncbi Agglomerative epigenetic aberrations are a common event in human breast cancer
    Petr Novak
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Cancer Res 68:8616-25. 2008
  4. ncbi Epigenetic inactivation of the HOXA gene cluster in breast cancer
    Petr Novak
    Arizona Cancer Center, Department of Pharmacology and Toxicology, Arizona Respiratory Center, University of Arizona, Tucson, Arizona, USA
    Cancer Res 66:10664-70. 2006
  5. ncbi The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells
    George S Watts
    Bone Marrow Transplant Program, Arizona Cancer Center and Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ 85724, USA
    Neoplasia 6:187-94. 2004
  6. ncbi Epigenetic regulation of the cell type-specific gene 14-3-3sigma
    Marc M Oshiro
    Pharmacology and Toxicology, University of Arizona, Arizona Cancer Center, Tucson, AZ 85724, USA
    Neoplasia 7:799-808. 2005
  7. ncbi Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells
    Damian J Junk
    Cancer Biology Graduate Interdisciplinary Program, The University of Arizona, Tucson, AZ 85724, USA
    Neoplasia 10:450-61. 2008
  8. ncbi Role for DNA methylation in the control of cell type specific maspin expression
    Bernard W Futscher
    Department of Pharmacology and Toxicology, Bone Marrow Transplant Program, Arizona Cancer Center, The University of Arizona, Tucson, Arizona 85724, USA
    Nat Genet 31:175-9. 2002

Collaborators

Detail Information

Publications8

  1. ncbi Epigenetic silencing of DSC3 is a common event in human breast cancer
    Marc M Oshiro
    Department of Pharmacology, Arizona Cancer Center, University of Arizona, Tucson, AZ, USA
    Breast Cancer Res 7:R669-80. 2005
    ..In this study, we examined the prevalence of epigenetic silencing of DSC3 gene expression in primary breast tumor specimens...
  2. ncbi Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression
    Marc M Oshiro
    Bone Marrow Transplant Program, Arizona Cancer Center and Department of Pharmacology and Toxicology, The University of Arizona, Tucson, AZ 85724, USA
    Oncogene 22:3624-34. 2003
    ..These results suggest that cancer treatments that target both genetic and epigenetic facets of gene regulation may be a useful strategy towards the therapeutic transcriptional reprogramming of cancer cells...
  3. ncbi Agglomerative epigenetic aberrations are a common event in human breast cancer
    Petr Novak
    Arizona Cancer Center, University of Arizona, Tucson, Arizona 85724, USA
    Cancer Res 68:8616-25. 2008
    ..Taken together, our results suggest that agglomerative epigenetic aberrations are frequent events in human breast cancer...
  4. ncbi Epigenetic inactivation of the HOXA gene cluster in breast cancer
    Petr Novak
    Arizona Cancer Center, Department of Pharmacology and Toxicology, Arizona Respiratory Center, University of Arizona, Tucson, Arizona, USA
    Cancer Res 66:10664-70. 2006
    ....
  5. ncbi The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells
    George S Watts
    Bone Marrow Transplant Program, Arizona Cancer Center and Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ 85724, USA
    Neoplasia 6:187-94. 2004
    ..Taken together, the results show that PCAF expression can be induced by wild-type p53...
  6. ncbi Epigenetic regulation of the cell type-specific gene 14-3-3sigma
    Marc M Oshiro
    Pharmacology and Toxicology, University of Arizona, Arizona Cancer Center, Tucson, AZ 85724, USA
    Neoplasia 7:799-808. 2005
    ..These findings extend the spectrum of cell type-specific genes controlled, partly, by normal epigenetic mechanisms, and suggest that this subset of genes may represent important targets of epigenetic dysregulation in human cancer...
  7. ncbi Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells
    Damian J Junk
    Cancer Biology Graduate Interdisciplinary Program, The University of Arizona, Tucson, AZ 85724, USA
    Neoplasia 10:450-61. 2008
    ..These changes may constitute novel biomarkers or reveal novel treatment modalities that could inhibit progression from primary to metastatic breast disease...
  8. ncbi Role for DNA methylation in the control of cell type specific maspin expression
    Bernard W Futscher
    Department of Pharmacology and Toxicology, Bone Marrow Transplant Program, Arizona Cancer Center, The University of Arizona, Tucson, Arizona 85724, USA
    Nat Genet 31:175-9. 2002
    ..These findings indicate that cytosine methylation is important in the establishment and maintenance of cell type restricted gene expression...